Our CEO Patrick Mooney recently chatted with Adil Ali, MD as part of Onyx's in-depth report Vital Signs: Future of Healthcare now published by Fortune. The feature spotlights our drug delivery platform and the potential to revolutionize #glaucoma treatment for patients by removing the daily treatment burden. Learn more about what is next for SpyGlass! Check out the article here: https://bit.ly/4fhymIE
Imagine never needing eyedrops again... I spoke with a biotech that’s replacing eyedrops with a single implant, placed during routine cataract surgery. The goal is no more daily drops for glaucoma. 💧👀 That’s the SpyGlass Pharma, Inc. vision, led by CEO Patrick Mooney, and I had the pleasure to sit down for a feature-length interview with Patrick for Vital Signs, produced by Onyx and now published in Fortune magazine. SpyGlass uses a proven medication, Bimatoprost, delivered through a tiny implant lasting three years. Early results are compelling: roughly 40% sustained IOP reduction at 18 months. With Phase II trials nearly complete and Phase III slated for 2025, SpyGlass is poised to redefine how we treat glaucoma. 👁️ Even better, they’re eyeing longer durations and expanding to other conditions like AMD. It’s a whole new way to see better outcomes in eye care: https://lnkd.in/ef7Qn4Qt